|
|
| | Navivumab Basic information |
| Product Name: | Navivumab | | Synonyms: | Navivumab;Research Grade Navivumab (DVV03803);Research Grade Navivumab;Navivumab (anti-HA) | | CAS: | 1443004-16-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Navivumab Structure]() |
| | Navivumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Navivumab Usage And Synthesis |
| Uses | Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2[1]. | | References | [1] Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis. 2018 Dec;31(6):527-534. DOI:10.1097/QCO.0000000000000499 |
| | Navivumab Preparation Products And Raw materials |
|